<DOC>
	<DOCNO>NCT02865109</DOCNO>
	<brief_summary>To provide access nusinersen eligible patient Infantile-onset Spinal Muscular Atrophy ( SMA ) ( consistent Type 1 ) address high-unmet medical need .</brief_summary>
	<brief_title>Expanded Access Program ( EAP ) Nusinersen Participants With Infantile-onset ( Consistent With Type 1 ) Spinal Muscular Atrophy ( SMA )</brief_title>
	<detailed_description>Availability nusinersen exist clinical trial site depend territory eligibility . Program opening date depend regulatory requirement center-specific factor . Participating site add apply EAP . A doctor must decide whether potential benefit outweighs risk receive investigational therapy base individual patient 's medical history program eligibility criterion . The Expanded Access Program United States close new patient enrollment nusinersen receive FDA approval .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Key Genetic documentation 5q SMA homozygous gene deletion , homozygous mutation , compound heterozygote . Onset clinical sign symptom â‰¤ 6 month ( 180 day ) age , consistent infantile onset , Type I SMA Patient whose care opinion treat physician meet , expect continue meet , guideline set 2007 Consensus Statement Standard Care SMA Key Patient qualify participate ongoing clinical trial nusinersen Participation prior nusinersen study Previous exposure nusinersen History brain spinal cord disease would interfere LP procedure CSF circulation Presence implant shunt drainage CSF implant CNS catheter Previous current participation clinical trial investigational gene therapy SMA Participation study investigational therapy SMA within 6 month five halflives investigational drug , whichever longer , prior first dose nusinersen . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>SMA</keyword>
	<keyword>SMN</keyword>
	<keyword>SMNRx</keyword>
	<keyword>ISIS-SMNRx</keyword>
	<keyword>ISIS-SMN Rx</keyword>
	<keyword>ISIS 396443</keyword>
	<keyword>ISIS-396443</keyword>
	<keyword>ENDEAR</keyword>
	<keyword>IONIS-SMNRx</keyword>
	<keyword>IONIS-SMN Rx</keyword>
	<keyword>EMBRACE</keyword>
	<keyword>NURTURE</keyword>
	<keyword>IONIS</keyword>
	<keyword>BIOGEN</keyword>
	<keyword>SHINE</keyword>
	<keyword>Nusinersen</keyword>
</DOC>